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Objective: To study the neurological symptoms of psoriasis patients who used inﬂiximab.
Methods: We studied psoriasis patients who used inﬂiximab in two referral general
hospitals in Tehran from January 2013 to January 2014. We completed neurological
symptoms checklists by questioning the patients.
Results: Sixty patients with psoriasis were included in this study. Among them, 3 pa-
tients had sensory symptoms as side effect and one patient showed motor symptoms as
side effect. There was no statistically signiﬁcant difference between age, gender, and
session count with the sensory and motor side effects (P > 0.05).
Conclusions: Neurological symptoms can be detected among 6% of patients under
treatment with inﬂiximab and there is no signiﬁcant association between symptoms and
gender, duration of drug use as well as age.1. Introduction
Psoriasis is a chronic inﬂammatory skin disease seriously
affecting the quality of life. Psoriasis is seen in 3% of population
worldwide. It is characterized with abnormal differentiation and
hyper-proliferation of keratinocytes [1]. The inﬂammatory
process in psoriasis is related to function of T lymphocytes in
dermal and epidermal layers. The predominant activity for T
helper-1 is releasing the tumor necrosis factor (TNF)-alpha,
interleukin-6, and interleukin-8 cytokines. The TNF-alpha is a
pro-inﬂammatory mediator playing the major role in classic
inﬂammation cascade [2].
Inﬂiximab is a monoclonal immunoglobulin G binding
exclusively to soluble and membranous TNF-alpha receptors
and leading to formation of antigen-antibody complex and in-
hibition of TNF-alpha binding to receptors which would result ininhibition of TNF-alpha biological activity [3,4]. Accordingly, it
would result in inhibition of exposure to pro-inﬂammatory
stimuli leading to decreased cell proliferation, the main charac-
teristic of psoriasis. Despite of the efﬁcacies of inﬂiximab, it
may bring some drug adverse effects [5].
Inﬂiximab is extensively utilized in treatment of psoriasis [6].
Some central nervous system demyelinization effects are
reported in patients under treatment with inﬂiximab [7]. Despite
low rate of adverse neurological effects, it is necessary to be
aware of them. Considering the importance of inﬂiximab use in
the treatment of psoriasis, increased use of this drug and also
low rate of researches on neurological side effects, this study
was performed to determine the neurological symptoms among
psoriasis patients under treatment with inﬂiximab.
2. Materials and methods
In this cross-sectional study, the understudy population
included 60 psoriasis patients attending to dermatology clinics in
two referral general hospitals from January 2013 to January
2014. A checklist including neurological symptoms was
completed by patients in person or via phone call. The variablesn access article under the CC BY-NC-ND
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wrist drop, ankle drop, claudicating gait, diplopia, visual loss,
painful eye movement, swallow disorder, speech disorder,
tingling, headache, seizure, nausea, and vomiting.
The data analysis was performed among 60 patients included
by SPSS 20.0 software (Chicago, Illinois, USA). Independent-
Sample-T and ANOVA tests were used and results were
considered statistically signiﬁcant at P values less than 0.05.
3. Results
In this study, 60 psoriasis patients including 21 women and
39 men were enrolled. The mean age was (37.70 ± 1.23) years
ranging from 14 to 70 years. The patients were received the drug
in a range from two to ten sessions and 53% were received three
sessions.
The sensory side effects were seen in three patients including
a 33-year-old male receiving three drug sessions (shown as
anesthesia of inferior lip and mandibular teeth for ten days), a
39-year-old patient who was received eight drug sessions
(experiencing tingling and anesthesia in palms and feet during
the ﬁrst 24 h with spontaneous improvement), and a 42-year-old
woman using drug for three sessions (experiencing the side ef-
fects after one week with tingling and anesthesia in both feet and
hands with spontaneous recovery), who decided to discontinue
the treatment. The motor side effect was only seen in a 40-year-
old man who was received six sessions of inﬂiximab leading to
transient stammering with spontaneous improvement and varied
time interval between drug uses and stammering. The patients
had no background disease and these symptoms were, for the
ﬁrst time, experienced by them. There was no statistically sig-
niﬁcant difference between age, gender, as well as session count
and the sensory and motor side effects (P > 0.05).
4. Discussion
In this study, the patients were most men from the age 30–40
years and receiving three drug sessions. There has been
increasing usage of inﬂiximab in treatment of psoriasis in recent
years and some researches however scarce, have shown some
neurological adverse effects of inﬂiximab [8]. Schnitzler et al.
evaluated 614 patients with Crohn's disease under treatment of
inﬂiximab and found three cases with neurological side
effects, compared with four out of sixty patients in our study [9].
The differences may be due to varied diseases in two studies
despite of the same loading and maintenance doses in two
studies including 5 mg/kg at base, the second and sixth weeks as
loading doses, and a maintenance dose of 5 mg/kg with eight-
week intervals. In some studies, neurological symptoms were
also reported in patients with rheumatoid arthritis receiving
inﬂiximab of 3 mg/kg for loading and maintenance doses with
same protocols. Another cause of difference between the results
found in various studies is the technique used for recognition of
neurological side effects. However, there was no study focusing
only on the neurological symptoms. Also, there was no similar
study only among the patients with psoriasis who were under
treatment with inﬂiximab. Cause of the neurological side effectsis demyelinization but the exact mechanisms are not clear yet
[10–12]. However, we only evaluated the symptoms without
diagnostic assessment. In our study, there was no signiﬁcant
association between neurological symptoms and gender,
duration of drug use as well as age. It may be due to small
sample size and larger studies need to be performed.
Finally, according to the obtained results, it can be concluded
that the neurological symptoms can be detected in 6% of pso-
riasis patients under treatment with inﬂiximab and there is no
statistically signiﬁcant association between symptoms and
gender, duration of drug use as well as age.
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